Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Miricorilant · CORT-118335

Small molecule · Modulator of glucocorticoid receptor (NR3C1) and mineralocorticoid receptor (NR3C2) · developed by Corcept Therapeutics

Phase 2 Most advanced trial (none active)

CORT Developer

7 Registered trials

What is Miricorilant?

Miricorilant is an orally bioavailable small molecule that acts as a selective glucocorticoid receptor mixed agonist/antagonist and mineralocorticoid receptor antagonist. It modulates cortisol-mediated pathways to improve lipid metabolism, reduce liver fat and inflammation, and enhance insulin sensitivity. It is studied in antipsychotic-induced weight gain, nonalcoholic steatohepatitis, and metabolic dysfunction-associated steatohepatitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: CORT-118335, Miricorlilant
Drug type: Small molecule
Targets: glucocorticoid receptor (NR3C1), mineralocorticoid receptor (NR3C2)
Mechanism: Modulator of glucocorticoid receptor (NR3C1) and mineralocorticoid receptor (NR3C2)
Pathways: lipid metabolism, insulin sensitivity
Therapy area: Psychiatry
Developer: Corcept Therapeutics (CORT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 311Y5GV21M

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06108219	Phase 2	Nonalcoholic Steatohepatitis (NASH)	Completed	CORT
NCT04524403	Phase 2	Antipsychotic-induced Weight Gain (AIWG)	Completed	CORT
NCT03818256	Phase 2	Antipsychotic-induced Weight Gain (AIWG)	Completed	CORT
NCT07240116	Phase 1	Healthy	Completed	CORT
NCT05117489	Phase 1	Nonalcoholic Steatohepatitis (NASH)	Completed	CORT
NCT04672499	Phase 1	Healthy	Completed	CORT
NCT03877562	Phase 1	Antipsychotic-induced Weight Gain	Completed	CORT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Antipsychotic-induced Weight GainAntipsychotic-induced Weight Gain (AIWG)HealthyMetabolic Dysfunction-associated Steatohepatitis (MASH)Nonalcoholic Steatohepatitis (NASH)

Other drugs acting on NR3C1 / NR3C2

Beclomethasone Dipropionate FDA approved Budesonide FDA approved IDP-118 FDA approved Infacort FDA approved Methylprednisolone FDA approved Mifepristone FDA approved Mometasone FDA approved Mometasone Furoate FDA approved Relacorilant FDA approved Chronocort Phase 3 Exicorilant Phase 1/2 ORIC-101 Phase 1

More from Corcept Therapeutics

Relacorilant FDA approved CORT125236 Phase 1 CORT125329 Phase 1 Dazucorilant Phase 2 Exicorilant Phase 1/2 Nenocorilant Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the CORT page.

Follow CORT, the company behind Miricorilant

See CORT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CORT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z